Search Results

Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans

https://www.seqirus.ca/news/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.ca/news

Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months

https://www.seqirus.ca/news/seqirus-receives-health-canada-approval-for-expanded-age-indication-for-people-as-young-as-6-months

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.seqirus.ca/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children

Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020

https://www.seqirus.ca/news/seqirus-presents-key-insights-on-influenza-vaccines

Seqirus Announces Health Canada Approval of Expanded Age Indication

https://www.seqirus.ca/news/seqirus-announces-health-canada-approval-of-expanded-age-indication

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

https://www.seqirus.ca/news/seqirus-announces-health-canada-approval-of--first-cell-based-seasonal-influenza-vaccine

Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.

https://www.seqirus.ca/our-company

Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.

https://www.seqirus.ca/our-company/leadership/stephen-marlow

Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.

https://www.seqirus.ca/